Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products

Kidney International

Volumn 59, Issue 1, 2001, Pages 348-357

  Rippe, Bengt ^a,b,c,d,e,f   Simonsen, Ole ^a,b,c,d,e,f   Heimbürger, Olle ^a,b,c,d,e,f   Christensson, Anders ^a,b,c,d,e,f   Haraldsson, Börje ^a,b,c,d,e,f   Stelin, Gunnar ^a,b,c,d,e,f   Weiss, Lars ^a,b,c,d,e,f   Nielsen, Finn David ^a,b,c,d,e,f   Bro, Susanne ^a,b,c,d,e,f   Friedberg, Michael ^a,b,c,d,e,f   Wieslander, Anders ^a,b,c,d,e,f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d and Centrallasarettet   (Sweden)

^e University of Copenhagen   (Denmark)

^f Gambro AB   (Sweden)

Author keywords

Biocompatible PD solution; Dialysate solutions; Interstitial damage; Peritonitis

Indexed keywords

3 DEOXYGLUCOSONE; 5 HYDROXYMETHYLFURFURAL; ACETALDEHYDE; CA 125 ANTIGEN; FORMALDEHYDE; FURFURAL; GAMBROSOL 40; GLUCOSE; GLYOXAL; HYALURONIC ACID; METHYLGLYOXAL; PEPTIDE; PERITONEAL DIALYSIS FLUID; PROCOLLAGEN 1 CARBOXY TERMINAL PEPTIDE; PROCOLLAGEN 3 AMINO TERMINAL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; PERITONEAL DIALYSIS; PERITONITIS; PH; PRIORITY JOURNAL; ULTRAFILTRATION;

EID: 0035162741     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00497.x     Document Type: Article

References (49)

1. Biocompatibility of peritoneal dialysis solutions
2. The effect of various dialysis solutions on peritoneal membrane viability
3. Role of glucose degradation products in the generation of characteristic AGE fluorescence in peritoneal dialysis fluid
4. Development of toxic degradation products during heat-sterilization of glucose-containing fluids for peritoneal dialysis: Influence of time and temperature
5. Potentially irritant glucose metabolites in unused CAPD-fluid
6. The heat-sterilization of fluids for peritoneal dialysis gives rise to several aldehydes
7. 3-Deoxyglucosone, a promoter of advanced glycation end-products in fluids for peritoneal dialysis
8. Toxicity of peritoneal dialysis fluids on cultured fibroblasts L-929
9. Heat-sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes
10. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro?
11. Cytotoxicity, pH and glucose degradation products in four different brands of PD-fluids
12. Cytotoxicity of peritoneal dialysis fluid: Is it related to glucose breakdown products?
13. Necrosis and apoptosis of polymorphonuclear cells exposed to peritoneal dialysis fluid in vitro
14. Acute in vivo toxicity of heat-sterilized glucose peritoneal dialysis fluids to rat peritoneal macrophages
15. Heat-sterilized PD-fluid blocks leukocyte adhesion and increases flow velocity in rat peritoneal venules
16. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats
17. The effect of shelf life of peritoneal dialysis fluid on ultrafiltration in CAPD
18. Impact of terminal heat-sterilization on the quality of peritoneal dialysis solutions
19. In vitro formation of advanced glycation end-products in peritoneal dialysis fluid
20. Glycation and advanced glycation end-products formation with icodextrin and dextrose
21. 2-microglobulin is modified with imidazolone, a novel advanced glycation end-product, in dialysis related amyloidosis
22. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
23. Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients
24. In vitro biocompatibility of a heat-sterilized low-toxic and less acidic fluid for peritoneal dialysis
25. Assessing the peritoneal dialysis capacities of individual patients
26. Simulations of peritoneal solute transport during continuous ambulatory peritoneal dialysis (CAPD): Application of two-pore formalism
27. Computer simulations of peritoneal fluid transport in CAPD
28. Less infusion pain and elevated level of CA 125 by the use of a new and more biocompatible PD-fluid
29. Alteration in water and solute transport with time on peritoneal dialysis
30. The biology of the mesothelium during peritoneal dialysis
31. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD
32. Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patient
33. Dialysate CA 125 in stable CAPD patients: No relation with transport parameters
34. Longitudinal follow-up of CA 125 in peritoneal effluent
35. Categorization of ultrastructural changes in the peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients
36. Peritoneal physiology: Transport of solutes
37. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective crossover study with a three-compartment bag
38. The source and possible significance of hyaluronan in the peritoneal cavity
39. The structure and function of hyaluronan: An overview
40. Effect of increased hydrostatic pressure on lymphatic elimination of hyaluronan from sheep lung
41. Collagen markers in peritoneal dialysis patients
42. Advanced glycation end-products reduce the viability of human peritoneal mesothelial cells
43. Issues affecting the longevity of the continuous peritoneal dialysis therapy
44. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain
45. Paradoxical effect of bicarbonate on cytoplasmic pH
46. Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents